IGF1: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<Structure load='1gzr' size='400' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' /> | <Structure load='1gzr' size='400' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' /> | ||
'''Insulin-like Growth Factor''' (IGF-1) is a member of the insulin protein family. '''Insulin''' is an essential endocrine protein. Indeed, it is the only hypoglycemic hormone of the human body. This protein is secreted in the beta cells of the Langerhans’ islet in the pancreas and takes part in the glycogenesis. This molecule helps the transportation of glucose into the cells, thus reducing the blood sugar rate, contrary to glucagon. | '''Insulin-like Growth Factor''' ('''IGF-1''') is a member of the insulin protein family. '''Insulin''' is an essential endocrine protein. Indeed, it is the only hypoglycemic hormone of the human body. This protein is secreted in the beta cells of the Langerhans’ islet in the pancreas and takes part in the glycogenesis. This molecule helps the transportation of glucose into the cells, thus reducing the blood sugar rate, contrary to glucagon. | ||
Insulin also has a huge effect on growth and thereby has a lot of structural similarities with its main associated growth factor: '''IGF-1''', aka somatomedin. Both share lots of properties thanks to their 60% similarity. | Insulin also has a huge effect on growth and thereby has a lot of structural similarities with its main associated growth factor: '''IGF-1''', aka somatomedin. Both share lots of properties thanks to their 60% similarity. | ||
IGF-1 is a peptidic hormone of 69 amino acids which is secreted by the liver. | IGF-1 is a peptidic hormone of 69 amino acids which is secreted by the liver. | ||
| Line 76: | Line 76: | ||
Growth failure, diabetes, cardiovascular pathology and others diseases such as Laron syndrom or cancers can be the consequences of an '''IGF-1 low level'''. | Growth failure, diabetes, cardiovascular pathology and others diseases such as Laron syndrom or cancers can be the consequences of an '''IGF-1 low level'''. | ||
Knowing that IGF-1 leads to cell proliferation with apoptose inhibition, if DNA undergoes alterations or mutations, those alterated cells will proliferate and survive even though it should result in their elimination by apoptose. Hence inducing '''cancer proliferation'''. <ref>R. Kaaks, Médecine Nucléaire - Imagerie fonctionnelle et métabolique, 2003, vol.27, n°1</ref> | Knowing that IGF-1 leads to cell proliferation with apoptose inhibition, if DNA undergoes alterations or mutations, those alterated cells will proliferate and survive even though it should result in their elimination by apoptose. | ||
Hence inducing '''cancer proliferation'''. <ref>R. Kaaks, Médecine Nucléaire - Imagerie fonctionnelle et métabolique, 2003, vol.27, n°1</ref> | |||
'''The Laron syndrom''', caused by mutation of GH genes, features growth failure and high insulin sensibility. Thus reducing concentration of GH receptors and inducing an IGF-1 low level. Treatment is based on biosynthetic IGF-1 carry out in mecasermin (a drug developed by Genentech) with IGFBP-3 and recombinant human IGF-1. One main side effect is hypoglycemia due to IGF-1 activity. <ref>https://en.wikipedia.org/wiki/Laron_syndrome, 26/01/2017</ref> | '''The Laron syndrom''', caused by mutation of GH genes, features growth failure and high insulin sensibility. Thus reducing concentration of GH receptors and inducing an IGF-1 low level. Treatment is based on biosynthetic IGF-1 carry out in mecasermin (a drug developed by Genentech) with IGFBP-3 and recombinant human IGF-1. One main side effect is hypoglycemia due to IGF-1 activity. <ref>https://en.wikipedia.org/wiki/Laron_syndrome, 26/01/2017</ref> | ||